Company profile
NOVARTIS AG
NYSE:NVSBiotechnology: Pharmaceutical Preparations
Drug pipeline (291)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ACYLANID | approved | — | 0 | — |
| ADAKVEO | approved | — | 0 | — |
| AFINITOR | approved | — | 132 | approved |
| AFINITOR DISPERZ | approved | — | 132 | approved |
| ALOMIDE | approved | — | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3129)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00219011 | phase3 | completed | 2005-05-01 | 2007-02-01 | Novartis | "ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure |
| NCT01197300 | phase3 | completed | 2010-10-25 | 2019-02-27 | Novartis Pharmaceuticals | 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids |
| NCT02756650 | phase2 | completed | 2016-06-23 | 2019-01-31 | Novartis Pharmaceuticals | 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement |
| NCT00929110 | phase3 | completed | 2009-06-01 | 2011-04-01 | Novartis | 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) |
| NCT01843348 | phase3 | completed | 2012-12-27 | 2016-03-23 | Novartis Pharmaceuticals | 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients |
FDA applications (208)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125856 | 2025-11-24 | BLA | NOVARTIS GENE THERAPIES, INC. | |||||
Loading… | ||||||||
| NDA 218436 | 2025-09-30 | NDA | NOVARTIS PHARMACEUTICALS CORP | |||||
Loading… | ||||||||
| NDA 219208 | 2025-04-02 | NDA | NOVARTIS PHARMACEUTICALS CORP | |||||
Loading… | ||||||||
| NDA 218466 | 2024-04-24 | NDA | NOVARTIS PHARMACEUTICALS CORP | |||||
Loading… | ||||||||
| NDA 218591 | 2024-04-12 | NDA | NOVARTIS PHARMACEUTICALS CORP | |||||
Loading… | ||||||||